| Nome |
# |
|
Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients, file e3835322-d391-15e8-e053-a505fe0a3de9
|
203
|
|
Is thyroid nodule location associated with malignancy risk?, file e383531f-bdad-15e8-e053-a505fe0a3de9
|
120
|
|
Cancer care during COVID-19 era: the quality of life of patients with thyroid malignancies, file e3835326-df83-15e8-e053-a505fe0a3de9
|
102
|
|
Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study, file e383531b-bc28-15e8-e053-a505fe0a3de9
|
91
|
|
A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal, file e3835322-cd5f-15e8-e053-a505fe0a3de9
|
89
|
|
Taller-than-wide shape: a new definition improves the specificity of TIRADS systems, file e3835325-0ec6-15e8-e053-a505fe0a3de9
|
88
|
|
Diagnostic performance of neck ultrasonography in the preoperative evaluation for extrathyroidal extension of suspicious thyroid nodules, file e383532b-a5e5-15e8-e053-a505fe0a3de9
|
83
|
|
Loss of function SETD2 mutations in poorly differentiated metastases from two Hürthle cell carcinomas of the thyroid, file e3835327-2503-15e8-e053-a505fe0a3de9
|
79
|
|
Genetic-clinical profile of subjects with apparently sporadic extra-adrenal paragangliomas, file e383531b-a8f7-15e8-e053-a505fe0a3de9
|
65
|
|
Prediction of response to vemurafenib in BRAF V600E mutant cancers based on a network approach, file e3835325-691d-15e8-e053-a505fe0a3de9
|
64
|
|
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study, file e383531b-5f28-15e8-e053-a505fe0a3de9
|
56
|
|
Fournier's gangrene during lenvatinib treatment: a case report, file e3835325-bccb-15e8-e053-a505fe0a3de9
|
48
|
|
Nuove frontiere nel carcinoma midollare della tiroide: identificazione di nuovi biomarkers diagnostici, file e3835329-61fb-15e8-e053-a505fe0a3de9
|
40
|
|
Contemporary thyroid nodule evaluation and management, file e3835326-7131-15e8-e053-a505fe0a3de9
|
14
|
|
Sonographic presentation of metastases to the thyroid gland: a case-series, file e383531b-4069-15e8-e053-a505fe0a3de9
|
11
|
|
Sonographically estimated risks of malignancy for thyroid nodules computed with five standard classification systems. Changes over time and their relation to malignancy, file e383531c-17c9-15e8-e053-a505fe0a3de9
|
8
|
|
Lack of association between obesity and aggressiveness of differentiated thyroid cancer, file e383531b-132e-15e8-e053-a505fe0a3de9
|
6
|
|
Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients, file e3835322-d407-15e8-e053-a505fe0a3de9
|
6
|
|
Variazioni epidemiologiche delle neoplasie tiroidee nel tempo: ruolo della nutrizione iodica, file e3835329-eaab-15e8-e053-a505fe0a3de9
|
6
|
|
Thyroid cancer patients with no evidence of disease: the need for repeat neck ultrasound, file e3835321-dfd0-15e8-e053-a505fe0a3de9
|
5
|
|
Changes in TSH levels in athyreotic patients with differentiated thyroid cancer during levothyroxine therapy: influence on dose adjustments, file e3835321-fa23-15e8-e053-a505fe0a3de9
|
5
|
|
Performance of a dual-component molecular assay in cytologically indeterminate thyroid nodules, file e3835325-736f-15e8-e053-a505fe0a3de9
|
5
|
|
Reducing the number of unnecessary thyroid biopsies while improving diagnostic accuracy: towards the "right" TIRADS, file e383531e-aa22-15e8-e053-a505fe0a3de9
|
4
|
|
Is it worth suppressing TSH in low- and intermediate-risk papillary thyroid cancer patients before the first disease assessment?, file e3835320-a4e7-15e8-e053-a505fe0a3de9
|
4
|
|
Hereditary neuroendocrine tumor syndromes, file e3835322-2f1c-15e8-e053-a505fe0a3de9
|
4
|
|
Targeted therapy with kinase inhibitors in aggressive endocrine tumors, file e3835322-d406-15e8-e053-a505fe0a3de9
|
4
|
|
Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma, file e3835324-e3b6-15e8-e053-a505fe0a3de9
|
4
|
|
Correction to. Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma, file e3835325-7152-15e8-e053-a505fe0a3de9
|
4
|
|
Analytical validation of a novel targeted next-generation sequencing assay for mutation detection in thyroid nodule aspirates and tissue, file e3835326-b466-15e8-e053-a505fe0a3de9
|
4
|
|
Selective use of radioactive iodine therapy for papillary thyroid cancers with low or lower-intermediate recurrence risk, file e3835329-3a59-15e8-e053-a505fe0a3de9
|
4
|
|
Predictive factors of response to mTOR inhibitors in neuroendocrine tumours, file e383531b-a8ea-15e8-e053-a505fe0a3de9
|
3
|
|
Prognosis of patients with differentiated thyroid carcinomas having a preoperative cytological report of indeterminate at low or high risk. A multicenter study, file e3835322-e2ae-15e8-e053-a505fe0a3de9
|
3
|
|
Computer-aided diagnostic system for thyroid nodule sonographic evaluation outperforms the specificity of less experienced examiners, file e3835325-55df-15e8-e053-a505fe0a3de9
|
3
|
|
Diagnostic performance of neck ultrasonography in the preoperative evaluation for extrathyroidal extension of suspicious thyroid nodules, file e3835329-de3e-15e8-e053-a505fe0a3de9
|
3
|
|
Prognostic role of the CDNK1B V109G polymorphism in multiple endocrine neoplasia type 1, file e383531b-5f1e-15e8-e053-a505fe0a3de9
|
2
|
|
Hepatic arterial embolization in patients with neuroendocrine tumors, file e383531b-a8ee-15e8-e053-a505fe0a3de9
|
2
|
|
Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases, file e3835322-d409-15e8-e053-a505fe0a3de9
|
2
|
|
null, file e3835322-d40d-15e8-e053-a505fe0a3de9
|
2
|
|
Sonographic risk stratification systems for thyroid nodules as rule-out tests in older adults, file e3835327-9e0b-15e8-e053-a505fe0a3de9
|
2
|
|
Tumor Related- and Non-tumor-Related Diarrhea in a Medullary Thyroid Cancer Patient, file e3835328-c39f-15e8-e053-a505fe0a3de9
|
2
|
|
Computer-aided diagnostic system for thyroid nodule sonographic evaluation outperforms the specificity of less experienced examiners, file 184b0eae-7565-4a11-94d3-47cca68fce30
|
1
|
|
Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1), file e383531b-5d6e-15e8-e053-a505fe0a3de9
|
1
|
|
CXCR4/CXCL12/CXCR7 axis is functional in neuroendocrine tumors and signals on mTOR, file e383531b-5d72-15e8-e053-a505fe0a3de9
|
1
|
|
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels, file e383531b-5d76-15e8-e053-a505fe0a3de9
|
1
|
|
Combined biological therapy with lanreotide autogel and cabergoline in the treatment of MEN-1-related insulinomas, file e383531b-5f1b-15e8-e053-a505fe0a3de9
|
1
|
|
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib, file e383531b-5f22-15e8-e053-a505fe0a3de9
|
1
|
|
Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1, file e383531b-5f2c-15e8-e053-a505fe0a3de9
|
1
|
|
Limitations of Chromogranin A in clinical practice, file e383531b-a8f2-15e8-e053-a505fe0a3de9
|
1
|
|
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET, file e383531b-a8fb-15e8-e053-a505fe0a3de9
|
1
|
|
Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication, file e383531b-aaa3-15e8-e053-a505fe0a3de9
|
1
|
|
Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation, file e383531b-aaa7-15e8-e053-a505fe0a3de9
|
1
|
|
Pituitary function and morphology in Fabry disease, file e383531b-ba72-15e8-e053-a505fe0a3de9
|
1
|
|
Thyroid function in Fabry disease before and after enzyme replacement therapy, file e383531b-ba76-15e8-e053-a505fe0a3de9
|
1
|
|
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours, file e383531b-bc1a-15e8-e053-a505fe0a3de9
|
1
|
|
Efficacy and safety of radiofrequency thermal ablation in the treatment of thyroid nodules with pressure symptoms in elderly patients, file e383531b-bc1e-15e8-e053-a505fe0a3de9
|
1
|
|
Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors, file e383531b-bc24-15e8-e053-a505fe0a3de9
|
1
|
|
Diagnosis and Differential Diagnosis of Medullary Thyroid Cancer, file e3835321-c865-15e8-e053-a505fe0a3de9
|
1
|
|
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses, file e3835322-badd-15e8-e053-a505fe0a3de9
|
1
|
|
Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism, file e3835322-d40b-15e8-e053-a505fe0a3de9
|
1
|
|
Thyroid hormone therapy in differentiated thyroid cancer, file e3835323-ecc4-15e8-e053-a505fe0a3de9
|
1
|
| Totale |
1.270 |